Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.cell.2021.02.042 http://scihub22266oqcxt.onion/10.1016/j.cell.2021.02.042 33735608!7901273!33735608     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cell 2021 ; 184 (9): 2362-2371.e9 Nephropedia Template TP {{tp|p=33735608|t=2021. SARS-CoV-2 501Y V2 variants lack higher infectivity but do have immune escape |pdf=|usr=}}{{33735608}} gab.com Text SARS-CoV-2 501Y V2 variants lack higher infectivity but do have immune escape JO: Cell http://www.kidney.de/pget.php?&tw=1&pmid=33735608 #FOAvip The 501Y.V2 variants of SARS-CoV-2 containing multiple mutations in spike are now dominant in South Africa and are rapidly spreading to other countries. Here, experiments with 18 pseudotyped viruses showed that the 501Y.V2 variants do not confer increased infectivity in multiple cell types except for murine ACE2-overexpressing cells, where a substantial increase in infectivity was observed. Notably, the susceptibility of the 501Y.V2 variants to 12 of 17 neutralizing monoclonal antibodies was substantially diminished, and the neutralization ability of the sera from convalescent patients and immunized mice was also reduced for these variants. The neutralization resistance was mainly caused by E484K and N501Y mutations in the receptor-binding domain of spike. The enhanced infectivity in murine ACE2-overexpressing cells suggests the possibility of spillover of the 501Y.V2 variants to mice. Moreover, the neutralization resistance we detected for the 501Y.V2 variants suggests the potential for compromised efficacy of monoclonal antibodies and vaccines. Twit Text FOAVip SARS-CoV-2 501Y V2 variants lack higher infectivity but do have immune escape ????Cell http://www.kidney.de/pget.php?&tw=1&pmid=33735608 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33735608 #FOAvip English Wikipedia <ref>{{Cite pmid|33735608}}</ref> SARS-CoV-2 501Y V2 variants lack higher infectivity but do have immune escape #MMPMID33735608 Li Q; Nie J; Wu J; Zhang L; Ding R; Wang H; Zhang Y; Li T; Liu S; Zhang M; Zhao C; Liu H; Nie L; Qin H; Wang M; Lu Q; Li X; Liu J; Liang H; Shi Y; Shen Y; Xie L; Zhang L; Qu X; Xu W; Huang W; Wang Y Cell 2021[Apr]; 184 (9): 2362-2371.e9 PMID33735608show ga The 501Y.V2 variants of SARS-CoV-2 containing multiple mutations in spike are now dominant in South Africa and are rapidly spreading to other countries. Here, experiments with 18 pseudotyped viruses showed that the 501Y.V2 variants do not confer increased infectivity in multiple cell types except for murine ACE2-overexpressing cells, where a substantial increase in infectivity was observed. Notably, the susceptibility of the 501Y.V2 variants to 12 of 17 neutralizing monoclonal antibodies was substantially diminished, and the neutralization ability of the sera from convalescent patients and immunized mice was also reduced for these variants. The neutralization resistance was mainly caused by E484K and N501Y mutations in the receptor-binding domain of spike. The enhanced infectivity in murine ACE2-overexpressing cells suggests the possibility of spillover of the 501Y.V2 variants to mice. Moreover, the neutralization resistance we detected for the 501Y.V2 variants suggests the potential for compromised efficacy of monoclonal antibodies and vaccines. |*Immune Evasion[MESH] |Angiotensin-Converting Enzyme 2/metabolism[MESH] |Antibodies, Monoclonal/immunology[MESH] |Antibodies, Neutralizing/immunology[MESH] |Antigens, Viral/immunology[MESH] |COVID-19/*immunology/*virology[MESH] |Cell Line, Tumor[MESH] |HEK293 Cells[MESH] |Humans[MESH] |Mutation/genetics[MESH]SARS-CoV-2 501Y V2 variants lack higher infectivity but do have immune(epmc).pdf DeepDyve Pubget Overpricing